Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes. 1986

G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott

Forty patients presenting with first episode genital herpes were randomly allocated to seven day treatment with oral acyclovir alone, placebo alone, oral acyclovir plus co-trimoxazole, or placebo plus co-trimoxazole. Patients receiving acyclovir had significantly shorter periods of viral shedding (p less than 0.001), pain (p = 0.03), and times to lesion healing (p less than 0.05). Averaged over all patients there was no evidence that co-trimoxazole affected any of the variables, though in women cotrimoxazole was associated with a shorter time to lesion healing (p less than 0.01). Furthermore, the combination treatment gave significantly shorter times to lesion healing than acyclovir alone, placebo alone, or placebo and co-trimoxazole (p = 0.01) and good trends elsewhere (external lesions and duration of pain). Neither drug was associated with any adverse events or toxicity or influenced the subsequent recurrence rate.

UI MeSH Term Description Entries
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
April 1988, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
January 1985, Scandinavian journal of infectious diseases. Supplementum,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
January 1985, Sexually transmitted diseases,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
September 1983, The Journal of antimicrobial chemotherapy,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
September 1983, The Journal of antimicrobial chemotherapy,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
May 1988, JAMA,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
February 1975, The British journal of clinical practice,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
August 1986, Journal of the American Academy of Dermatology,
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
September 1982, Lancet (London, England),
G R Kinghorn, and I Abeywickreme, and M Jeavons, and M Rowland, and I Barton, and G Al-Hasani, and C W Potter, and E Hickmott
September 1984, JAMA,
Copied contents to your clipboard!